Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001827506-25-000046
Filing Date
2025-04-21
Accepted
2025-04-21 16:08:01
Documents
15
Period of Report
2025-06-04

Document Format Files

Seq Description Document Type Size
1 DEF 14A trml-20250418.htm   iXBRL DEF 14A 456842
3 trml-20250418_g1.jpg GRAPHIC 89884
4 trml-20250418_g2.jpg GRAPHIC 2530879
5 trml-20250418_g3.jpg GRAPHIC 116316
  Complete submission text file 0001827506-25-000046.txt   6968172

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT trml-20250418.xsd EX-101.SCH 934
17 EXTRACTED XBRL INSTANCE DOCUMENT trml-20250418_htm.xml XML 3945
Mailing Address 27 WEST 24TH STREET SUITE 702 NEW YORK NY 10010
Business Address 27 WEST 24TH STREET SUITE 702 NEW YORK NY 10010 646-481-9832
Tourmaline Bio, Inc. (Filer) CIK: 0001827506 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-40384 | Film No.: 25853200
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)